Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503679
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 DC-853 on Midazolam Repaglinide Digoxin Rosuvastatin in Healthy Participants
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Single-center Open-label Fixed-sequence Crossover Study to Evaluate the Effect of LY4100511 DC-853 on the Single-dose Pharmacokinetics of Midazolam Repaglinide Digoxin and Rosuvastatin in Healthy Participants
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 DC-853 when administered alone or in the presence of cytochrome P450 substrates in healthy participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None